

Basic science: (March 2008)

1. Arendt LM, Schuler LA. Transgenic models to study actions of prolactin in mammary neoplasia. *J Mammary Gland Biol Neoplasia* 2008; **13**: 29–40.
2. Bai T, Luoh SW. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. *Carcinogenesis* 2008; **29**: 473–479.
3. Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambis S. A stromal gene signature associated with inflammatory breast cancer. *Int J Cancer* 2008; **122**: 1324–1332.
4. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. *Clin Cancer Res* 2008; **14**: 1340–1348.
5. Cha JY, Lambert QT, Reuther GW, Der CJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. *Mol Cancer Res* 2008; **6**: 435–445.
6. Chanrion M, Negre V, Fontaine H, Salvétat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. *Clin Cancer Res* 2008; **14**: 1744–1752.
7. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. *Clin Cancer Res* 2008; **14**: 1368–1376.
8. Cortesio CL, Chan KT, Perrin BJ, Burton NO, Zhang S, Zhang ZY, Huttenlocher A. Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. *J Cell Biol* 2008; **180**: 957–971.
9. Fitamant J, Guenebeaud C, Coissieux MM, Guix C, Trilleux I, Scoazec JY, Bachelot T, Bernet A, Mehlen P. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. *Proc Natl Acad Sci USA* 2008; **105**: 4850–4855.
10. Fletcher O, Johnson N, Gibson L, Coupland B, Fraser A, Leonard A, Silva ID, Ashworth A, Houlston R, Peto J. Association of genetic variants at 8q24 with breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 702–705.
11. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. *J Clin Oncol* 2008; **26**: 1260–1268.
12. Frank B, Wiestler M, Kropp S, Hemminki K, Spurdle AB, Sutter C, Wappenschmidt B, Chen XQ, Beesley J, Hopper JL, Meindl A, Kiechle M, Slinger T, Bugert P, Schmutzler RK, Bartram CR, Flesch-Janys D, Mutschelknauss E, Ashton K, Salazar R, Webb E, Hamann U, Brauch H, Justenhoven C, Ko YD, Bruning T, Silva IDS, Johnson N, Pharoah PPD, Dunning AM, Pooley KA, Chang-Claude J, Easton DF, Peto J, Houlston R, Chenevix-Trench G, Fletcher O, Burwinkel B. Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. *J Natl Cancer Inst* 2008; **100**: 437–442.
13. Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, Friedman E, Narod S, Olshen AB, Gregersen P, Kosarin K, Olsh A, Bergeron J, Ellis NA, Klein RJ, Clark AG, Norton L, Dean M, Boyd J, Offit K. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22-33. *Proc Natl Acad Sci USA* 2008; **105**: 4340–4345.
14. Goodell V, Waisman J, Salazar LG, dela Rosa C, Link J, Coveler AL, Childs JS, Fintak PA, Higgins DM, Disis ML. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. *Mol Cancer Ther* 2008; **7**: 449–454.
15. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to

- promote breast tumour growth and metastasis. *Nature* 2008; **452**: 187–U36.
16. Hanley K, Wang JM, Bourne P, Yang Q, Gao AC, Lyman G, Tang P. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. *Hum Pathol* 2008; **39**: 386–392.
 17. Hilton HN, Stanford PM, Harris J, Oakes SR, Kaplan W, Daly RJ, Ormandy CJ. KIBRA interacts with discoidin domain receptor 1 to modulate collagen-induced signalling. *Biochim Biophys Acta-Mol Cell Res* 2008; **1783**: 383–393.
 18. Hu P, Kinyamu HK, Wang LL, Martin J, Archer TK, Teng C. Estrogen induces estrogen-related receptor α gene expression and chromatin structural changes in estrogen receptor (ER)-positive and ER-negative breast cancer cells. *J Biol Chem* 2008; **283**: 6752–6763.
 19. Huang L, Cheng HC, Isom R, Chen CS, Levine RA, Pauli BU. Protein kinase C-E mediates polymeric fibronectin assembly on the surface of blood-borne rat breast cancer cells to promote pulmonary metastasis. *J Biol Chem* 2008; **283**: 7616–7627.
 20. Hurst DR, Xie Y, Vaidya KS, Mehta A, Moore BP, Accavitti-Loper MA, Samant RS, Saxena R, Silveira AC, Welch DR. Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. *J Biol Chem* 2008; **283**: 7438–7444.
 21. Kok M, Linn S, Laar R, Jansen M, Berg T, Delahaye L, Glas A, Peterse J, Hauptmann M, Foekens J, Klijn J, Wessels L, Veer L, Berns E. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. *Breast Cancer Res Treat* 2008; 10.1007/s10549-008-9939-y.
 22. Laffin B, Wellberg E, Kwak HI, Burghardt RC, Metz RP, Gustafson T, Schedin P, Porter WW. Loss of single-minded-2s in the mouse mammary gland induces an epithelial-mesenchymal transition associated with up-regulation of slug and matrix metalloprotease 2. *Mol Cell Biol* 2008; **28**: 1936–1946.
 23. Li Z, Wang C, Jiao X, Katiyar S, Casimiro MC, Prendergast GC, Powell MJ, Pestell RG. Alternate cyclin d1 mRNA splicing modulates p27(KIP1) binding and cell migration. *J Biol Chem* 2008; **283**: 7007–7015.
 24. Molli PR, Singh RR, Lee SW, Kumar R. MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene. *Oncogene* 2008; **27**: 1971–1980.
 25. Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek KD, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard MA, Chodosh LA, Pfeffer PL, Lindeman GJ, Visvader JE, Ormandy CJ. The Ets transcription factor Elf5 specifies mammary alveolar cell fate. *Genes Dev* 2008; **22**: 581–586.
 26. Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, Jones LA, Caan BJ, Stefanick ML, Hajek RA, Al-Delaimy WK, Stanczyk FZ, Pierce JP. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 614–620.
 27. Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stigibauer W, Kwasny W, Grill R, Stierer M, Gnant MFX, Filipits M. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. *Clin Cancer Res* 2008; **14**: 1767–1774.
 28. Stuedal A, Ma H, Bernstein L, Pike MC, Ursin G. Does breast size modify the association between mammographic density and breast cancer risk? *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 621–627.
 29. Takahashi M, Furihata M, Akimitsu N, Watanabe M, Kaul S, Yumoto N, Okada T. A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1. *Clin Exp Metastasis* 2008; 10.1007/s10585-008-9163-5.
 30. Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. *J Clin Pathol* 2008; **61**: 327–332.
 31. Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimaki A, Vierkant RA, Lingle WL, Frost MH, Hartmann LC. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. *J Natl Cancer Inst* 2008; **100**: 421–427.

Prepared by
R Sutherland
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia